Sanofi SA SNYNF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Recordati to Buy Global Rights to Sanofi's Enjaymo for $825 Million
-
Regeneron, Sanofi Get FDA OK of Dupixent for COPD — Update
-
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
-
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
-
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer Patients
-
FTC sues prescription-drug middlemen over insulin prices, says drugmakers are also 'on notice'
-
Regeneron, Sanofi Get FDA Approval for Upper Airway Disease Treatment
-
Sanofi Teams Up With RadioMedix, Orano in $352 Million Deal for Cancer Therapy — Update
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 11.83
- Price/Sales
- 2.64
- Dividend Yield (Trailing)
- 3.78%
- Dividend Yield (Forward)
- 3.78%
- Total Yield
- 4.05%
Company Profile
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 87,994
- Website
- https://www.sanofi.com
Competitors
Valuation
|
Metric
|
SNYNF
|
PFE
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 11.83 | 20.96 | 16.86 |
Price/Book Value | 1.86 | 1.85 | 6.39 |
Price/Sales | 2.64 | 2.90 | 4.48 |
Price/Cash Flow | 13.61 | 21.18 | 14.92 |
Price/Earnings
SNYNF
PFE
MRK
Financial Strength
|
Metric
|
SNYNF
|
PFE
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.52 | 0.51 | 0.88 |
Current Ratio | 1.00 | 0.86 | 1.47 |
Interest Coverage | 8.61 | −0.88 | 13.07 |
Quick Ratio
SNYNF
PFE
MRK
Profitability
|
Metric
|
SNYNF
|
PFE
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 7.59% | 3.50% | 15.46% |
Return on Equity (Normalized) | 14.17% | 8.28% | 41.15% |
Return on Invested Capital (Normalized) | 10.36% | 5.39% | 22.92% |
Return on Assets
SNYNF
PFE
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Qvyclrnmc | Qpzy | $798.8 Bil | |||
| Johnson & Johnson
JNJ
| Qwpphfbc | Pfl | $385.9 Bil | |||
| AbbVie Inc
ABBV
| Dcfkvrfgk | Vwcy | $343.2 Bil | |||
| Merck & Co Inc
MRK
| Btvkpfs | Pvb | $278.2 Bil | |||
| AstraZeneca PLC ADR
AZN
| Qcpvbkfy | Fpbv | $246.0 Bil | |||
| Roche Holding AG ADR
RHHBY
| Fywqmfhzn | Fwpsy | $244.4 Bil | |||
| Novartis AG ADR
NVS
| Tngrpxjzt | Wlf | $232.2 Bil | |||
| Amgen Inc
AMGN
| Pmtmnfjbq | Njph | $171.8 Bil | |||
| Pfizer Inc
PFE
| Nrrbxhxw | Gvhw | $162.0 Bil | |||
| Sanofi SA ADR
SNY
| Xstkgwypp | Vffw | $138.8 Bil |
United States